[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cad\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cad":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,76,110,136,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100311207","technical-development-of-cardiovascular-magnetic-resonance-imaging-cmr-using-a-low-specific-absorption-rate-sar-scanner-system-100311207",false,"NCT03331380","Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System","* INCLUSION CRITERIA:\n\nInclusion Criteria for All Participants (Objectives 1, 2, 3, and 4)\n\n* Men and women age greater than or equal to 18 years\n* Able to provide informed consent in writing\n* Willingness to cooperate with all study procedures (including food restriction) and available for scheduled study events\n\nInclusion Criteria for Healthy Volunteers (Objectives 1 and 2)\n\n-Currently healthy, self-reported\n\nInclusion Criteria for Subjects with Heart Disease (Objective 3)\n\n* Subjects having known heart disease including but not limited to\n* Stable angina pectoris due to epicardial coronary artery obstruction\n* Past myocardial infarction\n* Heart failure with reduced ejection fraction\n* Valvular heart disease\n* Pulmonary artery hypertension\n* Congenital heart disease with or without prior repair\n* Myocarditis\n* Infiltrative cardiomyopathy\n* Hypertrophic cardiomyopathy\n\nInclusion Criteria for Subjects with Non-Cardiac Disease (Objective 4)\n\n* Having known brain disease including but not limited to:\n\n  * Transient ischemic attack or stroke after 24 hours of onset\n  * Infection, inflammation meningitis\n  * Cognitive decline, neurodegenerative disorders\n  * Demyelinating disease, multiple sclerosis\n  * Loss of consciousness, seizures, epilepsy\n  * Brain tumor, metastases, abscess, lesion\n  * Vascular pathology\n  * Headache\n  * Hemorrhage\n  * Trauma\n* Have known musculoskeletal disease including but not limited to:\n\n  * Persistent neck pain or radiculopathy\n  * Cancer or tumors of the spine\n  * Congenital abnormalities of the spinal cord or knee\n  * Multiple sclerosis\n  * Injury or trauma\n  * Fracture evaluation\n  * Infectious or inflammatory processes\n  * Soft tissue damage\n  * Muscle or tendon disorders\n  * Knee meniscal disorders\n  * Marrow abnormalities\n  * Mechanical knee symptoms\n  * Vascular conditions\n* Have known abdominal diseases including but not limited to:\n\n  * Bowel obstruction\n  * Masses and tumors\n  * Crohns disease\n  * Diffuse liver disease such as hemochromatosis, hemosiderosis, fatty infiltration\n  * Focal hepatic lesions\n  * Cirrhotic liver\n  * Iron content determination\n  * Cystic kidney disease\n  * Vascular abnormalities\n* Have known lung disease including but not limited to:\n\n  * Cancer, tumors and masses\n  * Vascular and lymphatic abnormalities\n  * Pulmonary thromboembolic disease\n  * Trauma\n  * Suspected bronchiolitis\n  * Bronchiectasis or pneumonitis\n  * Asthma and other obstructive lung diseases\n  * Pulmonary lymphangioleiomyomatosis\n  * Cystic and interstitial lung diseases such as pulmonary lymphangioleiomyomatosis and cystic fibrosis\n* Have other known non-cardiovascular disease\n\nInclusion criteria for bronchodilators:\n\n\\- Only subjects who use bronchodilators routinely or those have undergone previous pulmonary function testing with bronchodilators will be invited to undergo bronchodilator testing during MRI.\n\nEXCLUSION CRITERIA:\n\nExclusion Criteria for All Participants:\n\n* Conditions that are thought to make MRI unsafe (that will be determined by filling out a separate form) including:\n\n  * Cerebral aneurysm clip unless it is labeled safe for MRI\n  * Neural stimulator (e.g. TENS-Unit) unless it is labeled safe for MRI\n  * Any type of ear implant unless it is labeled safe for MRI\n  * Ocular foreign body (e.g. metal shavings)\n  * Metal shrapnel or bullet\n  * Any implanted device (e.g. insulin pump, drug infusion device), unless it is labeled safe for MRI\n* Pregnancy. When uncertain, subjects will undergo either urine or serum pregnancy testing. Results from up to 3 days prior to the examination will be used. Post-menopausal and surgically sterilized subjects are exempt from this testing.\n\n  * If a urine or serum pregnancy test was administered as part of a referral protocol, and the test was administered up to 3 days prior to MRI examination for this protocol, a new pregnancy test will not be required for this protocol.\n  * If a pregnancy test has not been administered within 3 days of MRI examination for this protocol, a serum or urine pregnancy test will be administered. Medical personnel will determine which pregnancy test is appropriate based on subject s medical history, screening, and individual scenario. In addition, the subject will be asked if she may be pregnant prior to the performance of the MRI, even if the pregnancy test was negative within the past week. The pregnancy test will be repeated if she answers in the affirmative.\n\nExclusion Criteria for Gadolinium:\n\n-When gadolinium based contrast agent (GBCA) exposure is planned\n\n* Objective 1 and 2, Healthy Volunteers: No gadolinium based contrast agent exposure is permitted if eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m\\^(2) using the CKD-EPI equation or equivalent and a serum creatinine measured within 2 weeks without intercurrent change in medical condition or medications.\n* Objective 3 and 4, Volunteers with Cardiac and Non-Cardiac Disease: No gadolinium based contrast agent exposure is permitted if eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m\\^(2) using the CKDEPI equation \\[25\\] or equivalent and a serum creatinine measured within 2 weeks without\n\nintercurrent change in medical condition or medications.\n\n--For all objectives not more than two research MRI exams with GBCA exposure in a 12 month period. Research MRI exams performed outside of this protocol will be included in the 12 month period.\n\n* Subjects meeting this exclusion criterion, or without eGFR determination, may still be included in the study but may not be exposed to gadolinium-based contrast agents\n* Breast feeding (unless subject is willing to discard breast milk for 24 hours)\n* Does not wish to be exposed to gadolinium.\n\nExclusion Criteria for Oxygen Inhalation:\n\n* Severe chronic obstructive pulmonary disease defined as requiring more than one bronchodilator medication every day or continuous oxygen requiring\n* Prior treatment with bleomycin\n\nExclusion Criteria for Ferumoxytol Contrast\n\n* A history of allergic reaction to any intravenous iron product\n* Allergy to ferumoxytol or to mannitol excipient\n* Breast feeding\n* Does not wish to be exposed to ferumoxytol\n* Iron overload\n\nExclusion Criteria for oral contrast agent:\n\n* A history of reaction to oral contrast (if using barium sulfate)\n* Breast feeding unless subject is willing to discard breast milk for 24 hours (if using barium sulfate)\n* Allergy to pineapple (if using pineapple juice)\n* Does not wish to be exposed to oral contrast\n\nExclusion Criteria for Healthy Volunteers (Objectives 1 and 2)\n\n-Important past medical illness\n\nExclusion Criteria for Adults with heart Disease (Objective 3)\n\n* Unstable angina, acute coronary syndrome, or myocardial infarction not attributable to PCI, within 2 weeks unless after coronary revascularization of the culprit lesion.\n* Any hemodynamic instability or decompensated heart failure as determined by the enrolling physician.\n* Adenosine: Patients with asthma or chronic obstructive pulmonary disease of any severity are ineligible for vasodilator stress CMR with adenosine.\n* Regadenoson: Only patients with severe or uncontrolled asthma or severe or uncontrolled chronic obstructive pulmonary disease are ineligible for vasodilator stress CMR with regadenoson. This will be determined at the discretion of the supervising provider based on medical records and physical exam.\n* Patients with advanced heart block on baseline ECG are ineligible for vasodilator stress CMR\n\nExclusion Criteria for Adults with Non-Cardiac Disease (Objective 4)\n\n* Acute illness for which investigational imaging might delay care (such as acute stroke before treatment), as determined by the enrolling physician\n* Any hemodynamic instability as determined by the enrolling physician.\n\nExclusion criteria for bronchodilators:\n\n\\- Patient refuses bronchodilator administration.\n\nExclusion criteria for adults with cardiac implanted electronic devices (CIED, pacemakers or defibrillators:\n\nLow-SAR MRI:\n\n* Subjects with MRI-conditional and legacy CIEDs are not excluded, based on the intrinsic safety of low-SAR MRI.\n* Subjects with CIEDs are excluded if they have pacemakers implanted before 1998; ICDs implanted before 2000; temporary, epicardial or abandoned leads; and CIEDs implanted \\\u003C4 weeks prior to MRI exam.\n\nConventional MRI:\n\n-Subjects with CIED are excluded from conventional MRI unless they have CIEDs that are labeled as MRI conditional or MRI safe, and that are implanted greater than or equal to 4 weeks prior to MRI.",true,"ALL","18 Years","100 Years",{"count":20,"type":21},2950,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nResearchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools.\n\nObjective:\n\nTo test a new MRI scanner and software changes to create better pictures.\n\nEligibility:\n\nPeople with disease and healthy volunteers, ages 18 and older.\n\nDesign:\n\nParticipants will be screened with blood tests.\n\nParticipants may have both the new MRI and a conventional MRI or only the new one. If 2 are done, they must be within 60 days.\n\nFor both MRI versions, participants lie on a table that slides into a large tube. During scans, they will hold their breath for up to 20 seconds at a time. Heart activity will be measured by wires connected to pads on the skin. A flexible belt may be used to monitor their breathing. They will be in the scanner up to 2 hours.\n\nParticipants can agree to have a dye called gadolinium injected into their arm during the scan. This brightens the pictures.\n\nParticipants can agree to take a drug called a vasodilator. This helps detect areas of the heart with abnormal blood supply. Scans of the heart are taken before, during, and after they get the medicine. The drug may cause temporary chest pain or shortness of breath. They may get other drugs to relieve these symptoms.\n\nSponsoring Institution: National Heart, Lung, and Blood Institute",[27],"CAD",[29,30,31,32,33],"1.5 T CMR","Low SAR CMR","Gadolinium","Regadenoson","Adenosine","RECRUITING","2026-07-01",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2018-01-05",{"date":42,"type":21},"2028-05-31",{"name":44,"class":45},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100608761","phase-4-adding-lidocaine-to-custodiol-mixture-100608761","NCT07205757","Adding Lidocaine to Custodiol Mixture","Adding Lidocaine to Custodiol® Cardioplegia to Decrease Post-bypass Ventricular Arrhythmias in Adult Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery; A Prospective Randomized Double-Blinded Clinical Trial.","Inclusion Criteria:\n\n* patients scheduled for elective Coronary artery bypass grafting surgery\n\nExclusion Criteria:\n\n* Emergency or Redo surgery.\n* Baseline rhythm other than sinus rhythm\n* Any degree of heart block, bundle branch block or hemiblock\n* Known allergy to lidocaine.\n* Chronic kidney disease.\n* Hepatic impairment.\n* Severe psychiatric illness.",{"count":55,"type":21},70,[57],"PHASE4","The Bretschneider solution, also known as Custodiol, has been widely used in open-heart surgery requiring cardiopulmonary bypass (CPB) since its introduction in 1970. Custodiol is widely favored by cardiac surgeons, being administered as a single dose, and is supposed to offer myocardial protection for up to three hours, permitting an uninterrupted surgical time, especially for intricate procedures The literature continues to debate the superiority of custodial and other cardioplegic solutions, such as the Del Nido and St. Thomas solutions, regarding both short-term and long-term outcomes. Clinical trials and daily practice showed that the use of custodial cardioplegic solution is associated with increased incidences of ventricular arrhythmias, and subsequently, the use of a defibrillator after Aortic Cross Clamp (ACC) removal at the end of CPB when compared to other types of cardioplegia solutions .One of the reasons for this difference mentioned in the literature is the lidocaine contained in other types of cardioplegic solutions. Lidocaine acts as a membrane stabilizer by blocking rapid sodium channels in the heart, thus preventing arrhythmias, in addition to its ability to inhibit calcium influx, which is the primary cause of ischemic-reperfusion injury.\n\nBased on these data, the investigators hypothesize that the increased incidence of Ventricular arrhythmias with the use of Custodiol compared to other solutions, such as St Thomas and Del Nido, may be attributed to the absence of lidocaine. Although Custodiol contains tryptophan as a membrane-stabilizing component, it may be beneficial to add lidocaine to the Custodiol mixture to decrease the incidence of VF after cross-clamp removal in adult patients undergoing elective CABG.",[27,60],"Arrhythmia Ventricular",[62,63,64,65],"Custodiol","lidocaine","Bretschneider solution","Ventricular arrythmia","2025-11-14",{"date":68,"type":38},"2025-11-17",{"date":70,"type":38},"2025-10-03",{"date":72,"type":21},"2026-06-01",{"name":74,"class":75},"Fayoum University Hospital","OTHER",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100603448","custom-cadcam-insoles-for-plantar-pressure-improvement-in-foot-deformities-100603448","NCT07136649","Custom CAD\u002FCAM Insoles for Plantar Pressure Improvement in Foot Deformities","Effects of Custom CAD\u002FCAM Insoles on Plantar Pressure Distribution in Individuals With Foot Deformities: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-65 years\n* Clinically diagnosed with a foot deformity (e.g., pes planus, pes cavus, hallux valgus)\n* Able to use custom insoles for at least six months\n* Able to stand and walk for pedobarographic measurements\n* Willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Presence of neurological or systemic diseases affecting foot function (e.g., diabetic neuropathy)\n* History of lower extremity surgery in the last six months\n* Severe musculoskeletal conditions impairing sensorimotor function\n* Any condition preventing compliance with insole use\n* Contraindications for participating in gait or pressure measurements","65 Years",{"count":85,"type":21},30,[24],"This randomized controlled trial will investigate the effects of custom CAD\u002FCAM insoles on plantar pressure distribution and gait parameters in individuals with foot deformities, such as pes planus, pes cavus, and hallux valgus. A total of 30 participants will be randomly assigned to either the intervention group, receiving custom CAD\u002FCAM insoles, or the control group, receiving no insole intervention.\n\nPlantar pressure measurements will be performed using the As200 Gait Scan Pedobarography System at baseline and after eight weeks. Static and dynamic plantar pressure variables, contact area, and center of pressure displacement will be assessed, along with gait parameters including step length, step time, and walking speed.\n\nThe results of this study may contribute to the development of effective conservative treatment strategies to improve foot biomechanics and reduce pressure-related complications in individuals with foot deformities.",[89,90,91,27],"Foot Deformities","Orthotic Device","3D Printing",[93,94,95,96,97,98,91,99],"Custom CAD\u002FCAM Insoles","Pes Planus","Pes Planovalgus","Pes Cavus","Pedobarography","Plantar Pressure","Orthotics","NOT_YET_RECRUITING","2025-08-21",{"date":103,"type":38},"2025-08-22",{"date":105,"type":21},"2025-09-01",{"date":107,"type":21},"2025-11-30",{"name":109,"class":75},"Fenerbahce University",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":83,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100602848","effect-of-phase-i-cardiac-rehab-with-or-without-upper-limb-cycle-ergometer-100602848","NCT07128849","Effect of Phase I Cardiac Rehab With or Without Upper Limb Cycle Ergometer","Effects of Phase I Cardiac Rehabilitation With and Without Upper Limb Cycle Ergometer in Immediate Post-Operative Period of CABG","Inclusion Criteria:\n\n* Planned CABG patients\n* 40-65 years\n* Both male and female\n* Hemodynamic stable patients\n* Post extubation\n\nExclusion Criteria:\n\n* Patients suffering from pulmonary diseases and thyroid disorders\n* Mechanical ventilation more than 24 hr\n* Mean arterial pressure i.e, \\\u003C 60 mmHg or \\> 140 mmHg and heart rate not more than 120bpm\n* Having an orthopedic condition that makes the use of upper and lower extremity impossible.\n* Who have neurological impairment influencing breathing rate and heart rate.\n* Who required the implantation of an intra-aortic balloon during surgery\n* Who experienced postoperative complications such as pulmonary embolism","40 Years",{"count":119,"type":21},44,[24],"The aim of the study is to investigate the effects of an upper limb cycle ergometer in phase I CABG patients. This will likely enhance various outcomes such as quality of life, dyspnea, functional outcome measure, cardiovascular parameters, and upper limb mobility. If utilized, the arm ergometer may contribute to improve upper limb strength and endurance. This could result in improving upper limb range of motion and reducing the risk of adhesive capsulitis. This study will positively impact society by reducing morbidity and mortality rates, healthcare costs and ultimately improves patient care.",[27],[124,125,126],"phase I cardiac rehabilitation","upper limb cycle ergometer","post op period CABG","2025-08-18",{"date":129,"type":38},"2025-08-19",{"date":131,"type":38},"2025-07-17",{"date":133,"type":21},"2025-12-30",{"name":135,"class":75},"Riphah International University",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":46},"100465737","comparing-a-diagnostic-and-treatment-strategy-of-upfront-ctca-with-soc-in-patients-with-chest-pain-and-suspected-cad-100465737","NCT05344612","Comparing a Diagnostic and Treatment Strategy of Upfront CTCA With SOC in Patients With Chest Pain and Suspected CAD","Clinical Outcomes and Cost-effectiveness of a Diagnostic and Treatment Strategy of Upfront CTCA Plus Selective Non-invasive Functional Imaging Compared With Standard Care in Patients With Chest Pain and Suspected Coronary Artery Disease","CLEAR-CAD","Inclusion Criteria:\n\n* \\>18 years\n\nExclusion Criteria:\n\n* Presentation with acute coronary syndrome\n* Acute coronary syndrome within last 3 months\n* History of obstructive coronary artery disease on imaging\n* History of PCI and\u002For CABG\n* Severe renal failure\n* Severe allergy to ionidated contrast medium\n* Known pregnancy\n* Patients with an estimated life expectancy of less than 1 year",{"count":145,"type":21},6444,[24],"Rationale:\n\nPatients with chest pain usually undergo multiple diagnostic examinations to demonstrate or rule out atherosclerotic coronary artery disease (CAD). In addition to high healthcare costs, some of the examinations do not assess the presence of CAD, which means that patients may be undertreated and are at risk for myocardial infarction. A uniform diagnostic and treatment strategy that uses computed tomography coronary angiography (CTCA) as initial examination may reduce major adverse cardiac events (MACE) and may reduce healthcare costs. In addition, we hypothesize that this strategy improves angina-related health status and reduces the number of invasive coronary angiograms (CAG's).\n\nObjectives:\n\n* To show that the intervention is non-inferior to the control with regards to clinical outcomes\n* To show superiority of the intervention with regards to clinical outcomes\n\nStudy design: National multicenter prospective randomized controlled trial.\n\nStudy population: Patients with suspected stable CAD.\n\nIntervention: upfront CTCA to diagnose CAD and guide optimal medical therapy (OMT). Patients with obstructive CAD and refractory angina despite OMT will undergo non-invasive ischemia imaging to guide revascularization.\n\nControl: Standard of care. Diagnosis and treatment are at the discretion of the attending cardiologist.\n\nMain study end point: Composite of all-cause mortality and non-fatal myocardial infarction.",[149,27],"Chest Pain","2023-07-19",{"date":152,"type":38},"2023-07-20",{"date":154,"type":38},"2022-09-14",{"date":156,"type":21},"2026-09-30",{"name":158,"class":75},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":167,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100478364","ai-driven-national-platform-for-ct-coronary-angiography-for-clinical-and-industrial-applications-registry-100478364","NCT05509010","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)","APOLLO","Inclusion Criteria:\n\n1. Age ≥21 years old\n2. Signed informed consent\n3. Clinically indicated for evaluation by CTCA\n\nExclusion Criteria:\n\n1. Individuals unable to provide informed consent\n2. Known complex congenital heart disease\n3. Planned invasive angiography for reasons other than CAD\n4. Non-cardiac illness with life expectancy \\\u003C 2 years\n5. Pregnancy\n6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device\n7. Cardiac event and\u002For coronary revascularization (percutaneous coronary intervention (PCI) and\u002For coronary artery bypass grafting (CABG) and\u002For valvular repair\u002Freplacement prior to CTCA\n8. Glomerular Filtration Rate ≤ 30mL\u002Fmin\n9. Known allergy to iodinated contrast agent\n10. Contraindications to beta blockers or nitroglycerin or adenosine","21 Years","80 Years",{"count":170,"type":21},8000,"OBSERVATIONAL","The overall aim is to build an AI driven national Platform for CT cOronary angiography for clinicaL and industriaL applicatiOns (APOLLO) for automated anonymization, reporting, Agatston scoring and plaque quantification in CAD. It is a \"one-stop\" platform spanning diagnosis to clinical management and prognosis, and aid in predicting pharmacotherapy response.",[27,174,175,176],"Coronary Artery Disease","Coronary Stenosis","Plaques; Epicardial",[178,179],"CTCA","CT Coronary Angiography","2022-08-18",{"date":182,"type":38},"2022-08-19",{"date":184,"type":38},"2021-10-01",{"date":186,"type":21},"2027-12",{"name":188,"class":75},"National Heart Centre Singapore",3]